This is significant, as this CYPA-mediated HRR inhibition can be further exploited in a rational and targeted manner, as demonstrated here for MYCN-amplified NBm, MM and CML (Fig. 12; Dataset EV4). This evidence concerns the gene MYCN and chronic myelogenous leukemia, BCR-ABL1 positive.